China Pharma Net Worth
China Pharma Net Worth Breakdown | CPHI |
China Pharma Net Worth Analysis
China Pharma's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including China Pharma's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of China Pharma's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform China Pharma's net worth analysis. One common approach is to calculate China Pharma's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares China Pharma's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing China Pharma's net worth. This approach calculates the present value of China Pharma's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of China Pharma's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate China Pharma's net worth. This involves comparing China Pharma's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into China Pharma's net worth relative to its peers.
Enterprise Value |
|
To determine if China Pharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding China Pharma's net worth research are outlined below:
| China Pharma is way too risky over 90 days horizon | |
| China Pharma has some characteristics of a very speculative penny stock | |
| China Pharma appears to be risky and price may revert if volatility continues | |
| China Pharma has high likelihood to experience some financial distress in the next 2 years | |
| China Pharma Holdings currently holds 4.63 M in liabilities with Debt to Equity (D/E) ratio of 2.63, implying the company greatly relies on financing operations through barrowing. China Pharma Holdings has a current ratio of 0.74, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about China Pharma's use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 7.01 M. Net Loss for the year was (3.08 M) with profit before overhead, payroll, taxes, and interest of 349.27 K. | |
| China Pharma Holdings currently holds about 2.24 M in cash with (699.69 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.04. | |
| Roughly 51.0% of China Pharma shares are held by company insiders | |
| Latest headline from news.google.com: Bullish China NT Pharma Group Insider Buying Worth CN48.4m Yet To Pay Off - Simply Wall St |
China Pharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in China Pharma Holdings. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to China Pharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 12th of February 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Follow China Pharma's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.69 M.Market Cap |
|
Project China Pharma's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.22) | (0.23) | |
| Return On Capital Employed | (0.33) | (0.31) | |
| Return On Assets | (0.17) | (0.18) | |
| Return On Equity | (0.47) | (0.45) |
When accessing China Pharma's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures China Pharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of China Pharma's profitability and make more informed investment decisions.
Evaluate China Pharma's management efficiency
China Pharma Holdings has return on total asset (ROA) of (0.1754) % which means that it has lost $0.1754 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7489) %, meaning that it created substantial loss on money invested by shareholders. China Pharma's management efficiency ratios could be used to measure how well China Pharma manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.23. The China Pharma's current Return On Capital Employed is estimated to increase to -0.31. As of now, China Pharma's Intangible Assets are increasing as compared to previous years. The China Pharma's current Intangibles To Total Assets is estimated to increase to 0.21, while Total Assets are projected to decrease to under 18 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.53 | 2.41 | |
| Tangible Book Value Per Share | 1.29 | 1.23 | |
| Enterprise Value Over EBITDA | 716.67 | 752.50 | |
| Price Book Value Ratio | 0.25 | 0.26 | |
| Enterprise Value Multiple | 716.67 | 752.50 | |
| Price Fair Value | 0.25 | 0.26 | |
| Enterprise Value | 6 M | 5.7 M |
Examining the leadership quality of China Pharma Holdings offers valuable insights into its operational efficiency and financial health. This analysis assists investors in making informed decisions regarding the stock.
Enterprise Value Revenue 1.4414 | Revenue | Quarterly Revenue Growth (0.16) | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific China Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on China Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases China Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Liu Tao (chengdu) over six months ago Disposition of tradable shares by Liu Tao of China Pharma subject to Rule 16b-3 | ||
Liu Tao Chengdu over a year ago China Pharma exotic insider transaction detected | ||
Zhilin Li over a year ago Acquisition by Zhilin Li of 13757063 shares of China Pharma subject to Rule 16b-3 | ||
Deng Ke over a year ago China Pharma exotic insider transaction detected |
China Pharma Earnings per Share Projection vs Actual
When determining whether China Pharma Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of China Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of China Pharma Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on China Pharma Holdings Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in China Pharma Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of China Pharma. If investors know China will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about China Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.69) | Revenue Per Share | Quarterly Revenue Growth (0.16) | Return On Assets | Return On Equity |
The market value of China Pharma Holdings is measured differently than its book value, which is the value of China that is recorded on the company's balance sheet. Investors also form their own opinion of China Pharma's value that differs from its market value or its book value, called intrinsic value, which is China Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because China Pharma's market value can be influenced by many factors that don't directly affect China Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between China Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if China Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, China Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.